February 23, 2023 08:57 AM ESTUpdated February 24, 07:39 AM
Editor's note

Who are the young bio­phar­ma lead­ers mak­ing their mark in the in­dus­try? Nom­i­nate them for End­points' spe­cial re­port

Paul Schloesser

Associate Editor

Start­ing to­day, End­points News will be­gin ac­cept­ing nom­i­na­tions for our an­nu­al “20 Un­der 40” list.

Since 2020, End­points has pro­filed the biotech tal­ent …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times